Heart failure & cardiomyopathies
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B
Primary result · 6-minute walk test (6MWT)Result — go to the resultTreatment benefit +15 mAuthors' conclusion
In patients with ATTR-CM treated with patisiran, mean population-level differences of 7 to 8 m in 6MWT have practical relevance. The magnitude of the impact of patisiran on 6MWT performance over 12 months in APOLLO-B was associated with preserving the ability to perform activities of daily living.
Study context
- Population
- Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)randomized in APOLLO-B
- Participants
- 360 patients
- Comparison
- Patisiran vs placebo; change from baseline in 6MWT anchored to KCCQ-OS clinically important change categories
- Patisirann = 181
- Placebon = 179
- Primary endpoint
- 6-minute walk test (6MWT)
- Follow-up
- 12 months
Methodological detailsanchored to Kansas City Cardiomyopathy Questionnaire-Overall Summary score, proportional-odds cumulative logit model
- Anchored to Kansas City Cardiomyopathy Questionnaire-Overall Summary score
- Proportional-odds cumulative logit model
Primary result
As reported in the abstract
Treatment benefit
+15 m
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT · month 1215 m greater preservation · walking 1 block | 0.88 (0.83–0.93) | |
| Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT · month 1215 m greater preservation · climbing stairs | 0.84 (0.80–0.89) | |
| Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT · month 1215 m greater preservation · hurrying/jogging | 0.88 (0.83–0.93) | |
| Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT · month 1215 m greater preservation · dressing oneself | 0.85 (0.81–0.90) | |
| Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT · month 1215 m greater preservation · performing yard/housework or carrying groceries | 0.89 (0.84–0.93) | |
| 0.512Odds ratio (log scale) |
- Odds of deterioration in KCCQ Physical Limitation activities per 15 m greater preservation of 6MWT — approximately lower odds of deterioration
- 10% to 16%
Minimal clinically important difference in 6MWT
- Estimated minimal clinically important difference in 6MWT
- 6.9 to 7.8 m
Original publication
Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B. JACC Adv. Published 23 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →